ING Group’s Cellectis CLLS Stock Holding History

ING Group’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-193,615	Closed	-$1.78M	–	309
2020 Q1	$1.78M	Buy	+193,615	New	+$2.89M	0.08%	143

Other funds holding CLLS

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ING Group's CLLS Position: Q2 2020 in Review

ING Group sold out of Cellectis (CLLS) in Q2 2020, closing a stake of 193,615 shares — an estimated $1.78M sold.

ING Group first reported a position in CLLS in Q1 2020 and held it in 1 quarter. The position peaked at $1.78M in Q1 2020. 79 funds tracked by Wall St. Rank hold CLLS as of Q2 2020.

ING Group reported no remaining Cellectis position as of Q2 2020 after selling out during the quarter.
ING Group sold 193,615 Cellectis shares in Q2 2020, an estimated $1.78M.
ING Group first reported a position in Cellectis in Q1 2020 and held it in 1 quarter.
ING Group's Cellectis position peaked at $1.78M in Q1 2020.
79 funds tracked by Wall St. Rank held Cellectis as of Q2 2020.

Based on ING Group's 13F filing for Q2 2020, filed 13 Aug 2020.